Premium
Impact of acute kidney injury on overall survival in children and young adults undergoing allogeneic hematopoietic stem cell transplantation
Author(s) -
Matsuoka Daisuke,
Hirabayashi Koichi,
Murase Tsubasa,
Saito Shoji,
Nakazawa Yozo
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29167
Subject(s) - medicine , acute kidney injury , cumulative incidence , hematopoietic stem cell transplantation , incidence (geometry) , retrospective cohort study , complication , transplantation , kidney disease , physics , optics
Background Acute kidney injury (AKI) is a complication after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Increasing severity of AKI is associated with an increased risk of death. However, the impact of AKI in patients with malignant versus nonmalignant disease has not been reported. We investigated the incidence of AKI within the first 100 days after allo‐HSCT and the impact of AKI on both 3‐year overall survival (OS) and cumulative incidence of death after allo‐HSCT in all patients and in patients with/without malignant primary diseases. Methods We performed a retrospective analysis of 107 consecutive pediatric and young adult patients who received their first allo‐HSCT. AKI was classified into three grades according to the Acute Kidney Injury Network classification system. Results The cumulative incidences of AKI stages 1–3, 2–3, and 3, at day 100 after allo‐HSCT were 34.6% (95% confidence interval [CI], 25.7%–43.6%), 17.8% (95% CI, 11.2%–25.6%), and 3.7% (95% CI, 1.2%–8.6%), respectively. OS was reduced for patients with AKI compared with patients without AKI (60.4% vs. 79.6%, p = .038). The cumulative incidence of death in the AKI group with nonmalignant disease was significantly higher than that in the no‐AKI group (44.4% vs. 0%, p = .003). Conclusion AKI after allo‐HSCT was not only a frequent event but also related to reduced OS. We recommend that all patients receiving allo‐HSCT, especially patients with nonmalignant diseases, be closely monitored for AKI.